Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

@article{Koschmieder2016MyeloproliferativeNA,
  title={Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both},
  author={Steffen Koschmieder and Tariq I Mughal and Hans Carl Hasselbalch and Giovanni Barosi and P. Valent and J J Kiladjian and Georg Jeryczynski and Heinz Gisslinger and Jonas Samuel Jutzi and Heike Luise Pahl and Rȕdiger Hehlmann and Alessandro Maria Vannucchi and F Cervantes Cervantes and Richard T. Silver and Tiziano Barbui},
  journal={Leukemia},
  year={2016},
  volume={30},
  pages={1018-1024}
}
The Philadelphia-negative myeloproliferative neoplasms (MPNs) are clonal disorders involving hematopoietic stem and progenitor cells and are associated with myeloproliferation, splenomegaly and constitutional symptoms. Similar signs and symptoms can also be found in patients with chronic inflammatory diseases, and inflammatory processes have been found to play an important role in the pathogenesis and progression of MPNs. Signal transduction pathways involving JAK1, JAK2, STAT3 and STAT5 are… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Ruxolitinib therapy for myelofibrosis in Austria

  • Wiener klinische Wochenschrift
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 72 REFERENCES

Similar Papers